4.7 Article

Chitosan nanoparticle immersion vaccine offers protection against tilapia lake virus in laboratory and field studies

期刊

FISH & SHELLFISH IMMUNOLOGY
卷 131, 期 -, 页码 972-979

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.fsi.2022.10.063

关键词

Tilapia lake virus; Nanovaccine; Immunity; Immersion; Tilapia

资金

  1. Office of the Ministry of Higher Education, Science, Research and Innovation
  2. Thailand Science Research and Innovation through the Kasetsart University Reinventing University Program
  3. National Science and Technology Development Agency, Thailand [P-18-52277, P-19-50187]
  4. National Research Council of Thailand (NRCT) through the Royal Golden Jubilee PhD Program, Thailand [NRCT5-RGJ63002-037]

向作者/读者索取更多资源

The newly developed chitosan nanoparticle TiLV immersion vaccine showed promising efficacy in laboratory and field trials, with improved relative percent survival and specific antibody response in vaccinated fish. The use of this nanovaccine is convenient and suitable for mass vaccination to protect fish from TiLV infection.
Tilapia lake virus (TiLV), an enveloped negative-sense single-stranded RNA virus, causes tilapia lake virus disease (TiLVD), which is associated with mass mortality and severe economic impacts in wild and farmed tilapia in-dustries worldwide. In this study, we developed a chitosan nanoparticle TiLV immersion vaccine and assessed the efficacy of the vaccine in laboratory and field trials. Transmission electron microscopy showed that the inacti-vated vaccine had a particle size of 210.3 nm, while the nano inactivated vaccine had a spherical shape with a diameter of 120.4 nm. Further analysis using fluorescent staining and immunohistochemistry analysis revealed the mucoadhesive properties of the nanovaccine (CN-KV) through fish gills. We assessed the efficacy of an immersion-based TiLV nanovaccine using a cohabitation challenge model. The fish that received the nanovaccine showed better relative percent survival (RPS) at 68.17% compared with the RPS of the inactivated virus vaccine (KV) group at 25.01%. The CN-KV group also showed a higher TiLV-specific antibody response than the control and KV groups (p < 0.05). Importantly, under field conditions, the fish receiving the CN-KV nanovaccine had better RPS at 52.2% than the nonvaccinated control group. Taken together, the CN-KV nanovaccinated fish showed better survival and antibody response than the control and KV groups both under laboratory control challenge conditions and field trials. The newly developed immersion-based nanovaccine is easy to administer in small fish, is less labor-intensive, and allows for mass vaccination to protect fish from TiLV infection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据